Biopharm Co. Tarveda To Liquidate In Del. Chancery Court
A debt-burdened biopharmaceutical company unable to finance operations despite holding cancer treatment drug prospects potentially worth billions has moved to liquidate under an assignment of assets for the benefit of creditors...To view the full article, register now.
Already a subscriber? Click here to view full article